The Centers for Medicare & Medicaid Services (CMS) released its Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and.
NCPA submitted comments to CMS on its draft guidance to the Medicare Part D Manufacturer Discount Program, opposing any hypothetical DIR fees on drugs under the program. NCPA also supported provisions in the guidance around prompt payment and the requirements of manufacturers to provide CMS with labeler codes for all the manufacturer’s applicable drugs.